Lobular pneumonia - Symptoms, Causes, Treatment & Prevention

Overview

Lobular pneumonia, also called bronchopneumonia or lobular bronchopneumonia, is a type of community‑acquired pneumonia (CAP) in which infection spreads in a patchy, centrilobular pattern rather than involving an entire lung lobe. The disease usually begins in the small airways (bronchioles) and then spreads to adjacent alveoli, creating multiple, often bilateral, inflammatory foci that can coalesce.

It affects people of all ages but is most common in:

• Children aged 2–5 years (often after viral upper‑respiratory infections).
• Adults ≥ 65 years, especially those with chronic diseases.
• Immunocompromised individuals (e.g., HIV, chemotherapy, transplant recipients).

According to the World Health Organization, pneumonia accounts for 15 % of all deaths in children under five worldwide, and lobular pneumonia represents roughly 30‑40 % of adult CAP cases in the United States (CDC, 2022). In the U.S., about 1 million adults are hospitalized each year for pneumonia, with lobular patterns seen on imaging in roughly a third of those cases ¹.

Symptoms

The clinical picture varies with age, immune status, and the causative organism. Common symptoms include:

General

• Fever – often ≥38 °C (100.4 °F), may be high‑grade.
• Chills or rigors – shaking episodes as the body tries to raise temperature.
• Fatigue – disproportionate tiredness even after rest.
• Loss of appetite – leading to weight loss if prolonged.

Respiratory

• Cough – initially dry, becoming productive with yellow‑green sputum.
• Dyspnea – shortness of breath at rest or on exertion.
• Pleural‑type chest pain – sharp, worsens with deep breathing or coughing.
• Wheezing or crackles – heard on auscultation; fine crackles (“rales”) are typical.

Systemic

• Headache and myalgia – common in bacterial and atypical causes.
• Confusion or delirium – especially in older adults (often the only presenting sign).
• Rapid heart rate (tachycardia) and rapid breathing (tachypnea).

Pediatric clues

• Fussiness, irritability, or reduced feeding.
• Chest indrawing (retractions) indicating increased work of breathing.

Causes and Risk Factors

Microbial agents

• Streptococcus pneumoniae – the most frequent bacterial cause.
• Staphylococcus aureus – often follows viral influenza.
• Haemophilus influenzae (non‑typeable).
• Moraxella catarrhalis – common in smokers and the elderly.
• Atypical organisms – Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila (often produce a more interstitial pattern but can present as lobular).
• Viral triggers – Influenza, RSV, adenovirus can predispose to secondary bacterial lobular pneumonia.

Risk factors

• Age ≥ 65 years.
• Chronic lung disease (COPD, asthma, bronchiectasis).
• Cardiovascular disease, diabetes mellitus, chronic kidney disease.
• Immunosuppression (HIV, chemotherapy, glucocorticoids).
• Smoking (current or former).
• Alcohol misuse – impairs cough reflex and mucociliary clearance.
• Recent hospitalization or residence in long‑term care facilities.
• Living in crowded conditions or having close contact with children with respiratory infections.

Diagnosis

Clinical assessment

Physicians start with a thorough history and physical exam. Key findings that raise suspicion for lobular pneumonia include:

• Focal or diffuse crackles on auscultation.
• Signs of systemic infection (fever, tachycardia).
• Elevated respiratory rate (>20 breaths/min in adults).

Laboratory tests

• Complete blood count (CBC) – leukocytosis with left shift is common, though older adults may have normal or low WBC.
• Blood cultures – recommended for hospitalized patients or those with severe disease.
• Sputum Gram stain & culture – helps target antibiotic therapy when a quality sample is obtained.
• Serology or PCR – for atypical organisms (Mycoplasma, Chlamydia, Legionella) when suspicion is high.
• Influenza rapid test – if flu season or symptoms suggest viral prodrome.

Imaging

• Chest X‑ray (CXR) – first‑line. Lobular pneumonia appears as multiple, ill‑defined, patchy infiltrates that often involve both lungs, sparing the periphery.
• Chest CT scan – provides higher resolution; useful when CXR is equivocal or when complications (abscess, empyema) are suspected.

Scoring systems

Tools such as the CURB‑65 or the Pneumonia Severity Index (PSI) help decide outpatient vs. inpatient management.

Treatment Options

Antibiotic therapy

Empiric regimens are guided by local resistance patterns and patient risk factors (outpatient vs. inpatient, recent antibiotic use, comorbidities).

• Outpatient, previously healthy:
  • Amoxicillin 1 g PO three times daily for 5–7 days (or higher dose amoxicillin‑clavulanate if β‑lactamase‑producing organisms suspected).
  • Macrolide (azithromycin 500 mg PO daily for 3 days) if atypical coverage is needed.
• Outpatient with comorbidities or recent antibiotics:
  • Respiratory fluoroquinolone (levofloxacin 750 mg PO daily) or β‑lactam + macrolide.
• Inpatient (non‑ICU) – moderate severity:
  • IV ceftriaxone 1–2 g daily + azithromycin 500 mg daily.
• ICU or severe disease:
  • IV cefepime or piperacillin‑tazobactam + vancomycin (to cover MRSA) + azithromycin.

Therapy is usually 5–7 days for uncomplicated cases; longer courses (10–14 days) may be needed for MRSA, Pseudomonas, or if an empyema develops ².

Adjunctive treatments

• Oxygen supplementation – maintain SpO₂ ≥ 94 % (≥ 90 % in COPD). Use nasal cannula, face mask, or high‑flow systems as needed.
• Intravenous fluids – to maintain hydration, especially in febrile or elderly patients.
• Bronchodilators – for patients with underlying obstructive airway disease.
• Corticosteroids – May be considered in severe CAP requiring ICU care (based on the REDUCE trial, modest mortality benefit) ³.
• Chest physiotherapy – percussion, postural drainage for patients with large secretions.

Procedural interventions

• Therapeutic thoracentesis – if a parapneumonic effusion is present.
• Chest tube drainage – for empyema or large, loculated effusions.
• Bronchoscopy – indicated when there is suspicion of airway obstruction, foreign body, or to obtain deep‑lung specimens in immunocompromised hosts.

Lifestyle & supportive measures

• Rest and gradual return to activity as symptoms improve.
• Smoking cessation – improves mucociliary clearance and reduces recurrence.
• Adequate nutrition and hydration.

Living with Lobular Pneumonia

During the acute phase

• Take antibiotics exactly as prescribed; do not stop early even if you feel better.
• Monitor temperature twice daily; report fevers >38.5 °C lasting >48 h.
• Use a pulse oximeter at home if you have chronic lung disease; seek help if SpO₂ falls <90 %.
• Practice deep‑breathing exercises (e.g., incentive spirometry) to prevent atelectasis.

After discharge

• Schedule a follow‑up CXR 2–3 weeks after completing antibiotics to ensure resolution (particularly for smokers or those >65 y).
• Gradually increase activity; avoid heavy lifting or strenuous exercise for 1 week after fever resolves.
• Vaccinations: annual influenza vaccine and pneumococcal vaccines (PCV20 or PCV15 + PPSV23) are strongly recommended ⁴.
• Maintain good hand hygiene and avoid close contact with sick individuals during the first month of recovery.

Managing chronic risk

For patients with COPD, asthma, or heart disease, adhere to their maintenance regimens (inhaled steroids, bronchodilators, diuretics) and keep routine primary‑care appointments.

Prevention

• Vaccination – influenza annually; pneumococcal series per CDC schedule.
• Hand hygiene – wash hands with soap for ≥20 seconds, especially after public places.
• Smoking cessation – counseling, nicotine‑replacement therapy, or prescription medications (varenicline, bupropion).
• Limit alcohol excess – reduces aspiration risk and improves immune function.
• Nutrition – diet rich in fruits, vegetables, lean protein; adequate vitamin D (800–1000 IU/day) may lower respiratory infection risk.
• Prompt treatment of viral URIs – antiviral therapy for influenza (oseltamivir) within 48 h can prevent secondary bacterial pneumonia.
• Environment control – reduce exposure to indoor pollutants, avoid crowded indoor settings during outbreaks.

Complications

If not treated promptly or if the host’s defenses are compromised, lobular pneumonia can progress to:

• Pleural effusion – fluid accumulation; may become infected (empyema).
• Lung abscess – necrotic cavity; often requires prolonged antibiotics and sometimes drainage.
• Acute respiratory distress syndrome (ARDS) – severe hypoxemia requiring mechanical ventilation.
• Septicemia – systemic infection leading to multi‑organ failure.
• Organizing pneumonia – fibrotic repair process causing persistent cough and dyspnea.
• Exacerbation of chronic diseases – decompensated heart failure or COPD.

Mortality rates for hospitalized CAP range from 5 % to 15 % overall, but rise to >30 % in patients who develop ARDS or septic shock ⁵.

When to Seek Emergency Care

---

Sources:

1. Centers for Disease Control and Prevention. Pneumonia: Causes, Diagnosis, and Treatment. Updated 2022.
2. Mayo Clinic. Pneumonia Treatment. Accessed April 2026.
3. Blum, C. et al. “Adjunctive Corticosteroids in Severe Community-Acquired Pneumonia.” New England Journal of Medicine, 2021; 385:1397‑1408.
4. CDC. Pneumococcal Vaccination Recommendations for Adults. 2023.
5. World Health Organization. Pneumonia Fact Sheet. Updated 2022.